NCT05431504尚未招募2 期
An Exploratory Trial of Dalpiciclib in Combination With Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2022年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- 6-month-OS rate
研究概览
简要总结
This is a multicenter, single-arm, open-label, Simon's two-stage exploratory clinical trial. 18 eligible patients with advanced breast cancer with visceral crisis will enroll in stage I. If the study enter stage 2 and continue to include 53 assessable subjects (35 in stage 2). All eligible patients will receive Dalpiciclib plus endocrine therapy chosen by the Physicians until disease progression, death or intolerable toxicity. Tumor assessment was conducted according to RECIST 1.1 criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal or premenopausal/perimenopausal women aged ≥18 meet one of the following:
- •A) Previous bilateral oophorectomy, or age ≥60 years; or B) age<
- •Natural postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without other pathological or physiological causes), E2 and FSH at postmenopausal levels; or C) premenopausal/perimenopausal women must receive LHRH agonists therapy during the study.
- •Female breast cancer patients diagnosed as HR-positive or HER2-negative by pathological examination are not suitable for surgical resection or radiotherapy for the purpose of cure.
- •A) ER-positive and/or PR-positive are defined as: ≥ 1% of all tumor cells are positively stained (confirmed by investigator review at the site); B) HER2-negative are defined as: 0/1 + by standard immunohistochemistry (IHC); HER2/CEP17 ratio less than 2.0 by ISH or HER2 gene copy number less than 4 (confirmed by investigator review at the site).
- •Any clinical signs or symptoms of symptomatic brain metastasis or visceral metastasis (at least one of the following: carcinomatous meningitis or leptomeningeal metastasis; pleural effusion; ascites; abdominal pain caused by liver or peritoneal metastasis; dyspnea caused by pleural effusion or pulmonary lymphangitis; elevated liver enzymes (> 2 × ULN); rapid elevation of bilirubin > 1.5 × ULN in the absence of Gilbert's syndrome or biliary obstruction; pathologically confirmed bone marrow metastasis; hemoglobin less than 10 g) and patients who cannot tolerate chemotherapy or are considered by the investigator to be inappropriate for chemotherapy or chemotherapy.
- •Adequate bone marrow function. Definitions are as follows: a) neutrophil count (ANC) ≥ 1,500/mm3 (1.5 x 109L) (14 without growth factors); b) platelet count (PLT) ≥ 100,000/mm3 (100 x 109L) (7 without correction); c) hemoglobin (Hb) ≥ 8 g/dL (80 g/L) (7 without correction).
- •Female subjects who are not postmenopausal or surgically sterile must have a serum pregnancy test within 7 days before the first dose and have a negative result, and are willing to abstain from sexual intercourse or use a medically recognized highly effective contraceptive measure after signing the informed consent, during the study, and for 1 year after administration of the study drug.
- •Voluntarily participate in this study, sign informed consent, have good compliance and are willing to cooperate with follow-up.
排除标准
- •Patients contraindicated with dalpiciclib.
- •Patients with primary resistance to endocrine therapy. Relapse within 2 years of adjuvant endocrine therapy, or disease progression within 6 months of advanced first-line endocrine therapy.
- •Patients with more than 3 lines of prior endocrine therapy.
- •Patients previously treated with any CDK4/6 inhibitor.
- •Patients with simple bone metastasis.
- •Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥ 1000 IU/ml), hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method) or combined hepatitis B and C co-infection.
- •Within 6 months before enrollment, the following conditions occur: myocardial infarction, severe/unstable angina pectoris, NYHA grade 2 or higher cardiac insufficiency, ≥ grade 2 persistent arrhythmia (according to NCI CTCAE v5.0), atrial fibrillation of any grade, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack) or symptomatic pulmonary embolism.
- •Severe infection occurring within 4 weeks (such as intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical practice) before the first dose, or unexplained fever > 38.5℃ during screening/before the first dose.
- •Inability to swallow, intestinal obstruction, or other factors affecting drug administration and absorption.
- •Known hypersensitivity to dalpiciclib and any of its excipients.
- •Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- •Known history of psychiatric drug abuse or drug use;
- •Female patients who are pregnant or lactating.
- •Any other condition that the investigator considers the subject unsuitable for this study.
研究组 & 干预措施
Treatment group
Experimental
Dalpiciclib in combination with endocrine therapy by physicians choice
干预措施: Dalpiciclib in combination with endocrine therapy by Physicians choice (Drug)
结局指标
主要结局
6-month-OS rate
时间窗: From the start of treatment to 6 month
6-month-Overall Survival rate. Overall Survival , defined as the time from the start of treatment to the date of death, regardless of the cause of death.
次要结局
- Duration of Response (DoR)(From the start of treatment to 36 month)
- Overall Survival (OS)(From the start of treatment to 36 month)
- Clinical Benefit Response (CBR)(From the start of treatment to 36 month)
- 1-year-OS rate(From the start of treatment to 12 month)
- Progression-Free Survival (PFS)(From the start of treatment to 36 month)
- Objective Overall Response Rate (ORR)(From the start of treatment to 36 month)
- Time to response（TTR）(From the start of treatment to 36 month)
- Time to treatment failure (TTF)(From the start of treatment to 36 month)
- Adverse events (AEs)(From the start of treatment to 36 month)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast CancerBreast CancerNCT06605690Liu Shu30
招募中
2 期
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06684600Peking University35
招募中
2 期
Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast CancerBreast CancerNCT04997798First Affiliated Hospital of Zhejiang University30
招募中
1 期
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensHER2-positive Gastric CancerHER2-positive Gastroesophageal Junction AdenocarcinomaNCT06572319Zhejiang Cancer Hospital35
招募中
2 期
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.Advanced HR-positive and HER2-negative Breast Cancer CDK4/6 Inhibitor Treatment FailedNCT06133088Zhejiang Cancer Hospital53